Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. The potency of Afatinib (BIBW 2992) on the EGFR and HER2 kinases revealed IC50 values of 0.5 nM and 14 nM, respectively. Afatinib (BIBW 2992) suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.
Another CAS# 439081-18-2
Clin Transl Oncol. 2023 May;25(5):1425-1435.
ADAM12 promotes gemcitabine resistance by activating EGFR signaling pathway and induces EMT in bladder cancer
Afatinib (BIBW 2992) purchased from AbMole
J Virol. 2020 Feb 14;94(5):e01791-19.
Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use
Afatinib (BIBW 2992) purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | NSCLC cells H1666, H3255 and NCI-H1975 |
Preparation method | Growth inhibition of lung cancer cell lines by BIBW2992 and other EGFR and/or HER2 inhibitors (a) Sensitivity of NSCLC cell lines that express EGFR WT, Exon 19 Del, L858R/ T790M and HER2 INS776V to BIBW2992 and erlotinib. Dose-dependent growth inhibition was determined by MTS assay. Only HCC827 cells are sensitive to erlotinib whereas NCIH1781 and NCI-H1975 cells are also sensitive to BIBW2992. Points, average of two independent experiments, each done in triplicate; bars, s.d. *A549 cells harbor a Kras G12S mutation. See also in Supplementary Table 4. (b) Inhibition of anchorage independent cell proliferation of various lung cancer cell lines treated with BIBW2992, lapatinib, canertinib, gefitinib or erlotinib. The IC50 values were determined as described. |
Concentrations | 0~10µM |
Incubation time | 72 h |
Animal Experiment | |
---|---|
Animal models | A431 cells mouse bearing tumor xenograft model |
Formulation | 0.5% methocellulose-0.4% polysorbate-80 (Tween 80) |
Dosages | 20 ml/kg body weight once daily |
Administration | oral gavage |
Molecular Weight | 485.94 |
Formula | C24H25ClFN5O3 |
CAS Number | 850140-72-6 |
Form | Solid |
Solubility (25°C) | DMSO ≥ 80 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related EGFR/HER2 Products |
---|
BBT-207
BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity. |
VRN-11
VRN-11 is an EGFR C797S inhibitor. |
TRX-221
TRX-221 is an EGFR C797S inhibitor. |
TAS-3351
TAS-3351 is an EGFR C797S inhibitor. |
Larotinib mesylate hydrate
Larotinib mesylate hydrate is a potent, broad-spectrum, orally active tyrosine kinase inhibitor (TKI) that primarily targets EGFR with an IC50 of 0.6 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.